STEPHEN SELIGER, MD



Curriculum Vitae

Stephen L. Seliger, M.D., M.S.

Associate Professor, Department of Medicine

University of Maryland School of Medicine

Attending Physician, BVAMC

Date 9/12/2016

Contact Information

Division of Nephrology

University of Maryland School of Medicine

22 S. Greene St. N3W143

Baltimore, MD 21201

(410) 605-7000 x5231

Fax (410 )605-7489

sseliger@medicine.umaryland.edu

Education

1988-1992 B.A. Columbia College, Columbia University, New York, NY

Major: Greek

1992-1996 M.D. New York University School of Medicine, New York, NY

Major: Physiology and Neuroscience

2000-2002 M.S. Department of Epidemiology, School of Public Health

University of Washington, Seattle, WA

Thesis: “HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients”

Post-Graduate Education and Training

1996-1999 Residency, Internal Medicine

Columbia Presbyterian Medical Center, Columbia University, New York, NY

1999-2003 Clinical and Research Nephrology Fellowship

Division of Nephrology, University of Washington, Seattle, WA

Medical Licensure

State of Washington (Inactive)

State of Maryland, Physician and Surgeon (Active)

Employment History

Academic Appointments

2003-2004 Acting Instructor in Medicine

University of Washington School of Medicine

2005-2012 Assistant Professor in Medicine

University of Maryland School of Medicine (UMSOM)

2005-2012 Assistant Professor in Epidemiology & Public Health (secondary), UMSOM

2012-present Associate Professor in Medicine

University of Maryland School of Medicine (UMSOM)

2012-present Associate Professor in Epidemiology & Public Health (secondary), UMSOM

Other Employment

2003-2005 Attending Physician

University of Washington Medical Center

2003-2005 Attending Physician

Harborview Medical Center, Seattle, WA

2005-present Attending Physician

Baltimore VA Medical Center

2005-present Attending Physician

University of Maryland Medical Center

Professional Memberships

2001-present American Society of Nephrology

2001-present American Heart Association

2002-present International Society of Nephrology

Honors and Awards

1988-1992 Dean’s List, Columbia College, Columbia University

1996 Honors in Physiology and Neuroscience, New York University School of Medicine

2011 Clinical Publication of the Year, Department of Medicine, University of Maryland School of Medicine

2012 Clinical Publication of the Year, Department of Medicine, University of Maryland School of Medicine

Administrative Service

Institutional Service

2006-present Member, UMB Institutional Review Board

2008-2010 Representative, UMSOM Council

2009-2014 Vice-Chair, UMB Institutional Review Board

2014-2015 Acting Section Head, Nephrology, BVAMC

2015-present Chair, University of Maryland, Baltimore Older Americans Independence Center DSMB

National Service

2003-present Ad Hoc Reviewer, Journal of the American Society of Nephrology

2003-present Ad Hoc Reviewer, Kidney International

2004-2012 Ad Hoc Reviewer, American Journal of Kidney Disease

2005 -2008 Member, Editorial Board – Journal of the American Society of Nephrology

2005-2007 Member, Study Design Committee – Chronic Renal Insufficiency Cohort (CRIC) Study

2006-present Member, Study Design and Executive Committees, VA Co-Operative Study Program (CSP) #565

2007-present Member, Medical Review Board, Mid-Atlantic Renal Coalition (ESRD Network 5)

2008-2010 Grant Reviewer, NIH/NCCAAM

2009-present Ad Hoc Reviewer, Neurology

2010-2013 Member, VA Merit Review Rehabilitation Research & Development Review Committee #4 – Psychosocial Health and Social Reintegration.

2014-present Chairperson – VA Merit Review Rehabilitation Research & Development Review Committee #4 – Psychosocial Health and Social Reintegration

2011-present Ad Hoc Reviewer, JAMA

2011-2013 Member, National Steering Committee, National Kidney Foundation Kidney Early Evaluation Program (KEEP).

2011-present Grant Reviewer, NIH/NIDDK (Special Emphasis Panels)

2011-2016 Member, Editorial Board - Clinical Journal of the American Society of Nephrology

2012-present Associate Editor, American Journal of Kidney Disease (AJKD)

2013-2014 Member, Kidney Disease Improving Global Outcomes (KDIGO) Task Force on Advance Care Planning and Shared-Decision Making.

2013 Member, American Association of Clinical Chemistry (AACC) Lab Tests Online Pro Task Force

2014 Member, CMS Functional Status Technical Expert Panel (TEP)

2015-present Co-Editor, Evidence-Based Nephrology Series, Clinical Journal of the American Society of Nephrolog y (CJASN)

2015-present Member, Executive Committee, Coalition for Supportive Care of Kidney Patients (CSCKP)

2016-present Member, Event Adjudication Committee, SONAR clinical trial

2016-present Member, Editorial Board, Circulation [incoming member]

2016-present Associate Editor, Clinical Journal of the American Society of Nephrology

Grant Support

Active

10/1/2015-9/30/2019 (Co-Investigator, 10%) PI: Katzel

VA National Safety for Patient Center

“Baltimore Patient Safety Center of Inquiry”

Role: Co-Investigator

7/1/2015-6/30/2012 (Director, Clinical Core) PI: Watnick

NIH/NIDDK 2 P30DK090868-07

“Baltimore PKD Research & Clinical Core Center”

Role: Director, Clinical & Translational Core

9/30/15-9/29/20 (Co-Investigator, 10%) PI: Bae

Dept of Defense W81XWH-15-1-0663

“Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease”

Role: Co-Investigator

9/01/11-8/30/2017 (Co-PI,15%) PI: Seliger

(NCE) NIH/NIDDK R01-DK090401

“Exercise training and cognitive and physical function in CKD”

Role: Co-Principal Investigator

Pending Grants

11/1/2016-10/30/2017 (Co-PI, 10%) PI: Seliger/deFilippi

Roche Diagnostics, LLC.

“Malignant Left Ventricular Hypertrophy (LVH) and Development of Heart Failure: Pilot Study”

Role: Co-Principal Investigator

12/1/16-11/30/17 (co-PI, 10%) PI: Seliger/deFilippi

Roche Diagnostics, LLD

“Multi-study incident heart failure risk prediction modeling”

Role: Co-Principal Investigator

Completed Grants

12/1/02-11/31/07 (PI, 75%)

“Chronic Renal Dysfunction and Ischemic Brain Disease”

NIH/NIDDK 5K23 DK063079

Roles: Principal Investigator.

7/1/05-6/30/07 (PI)

“Cerebral Hypoperfusion and Physical and Cognitive Function in Chronic Kidney Disease”

University of Maryland Claude D. Pepper OAIC Research Development Core Pilot Grant

9/30/05-7/31/09 (Significant Contributor) PI: Sarnak

“Does Kidney Function Determine Aging Success”

NIH/NIA R01 AG027002-01

7/1/06-6/30/07 (PI)

“Nitric Oxide and Oxidative Stress as Predictors of Brain Structure and Function in CKD”

National Kidney Foundation of Maryland

9/1/06-8/31/2008 (Co-Invest, 10%) PI: DeFilippi

“Role of NT-proBNP for detecting structural heart disease and predicting risk of new onset heart failure or cardiovascular death in an ambulatory elderly cohort”

Roche, Inc

12/1/06-11/30/07 (PI, 5%)

“Risk Factors and Consequences of Regional Cerebral Hypoperfusion in Older Adults– a Perfusion Magnetic Resonance Study”

VA Maryland Healthcare System REAP Pilot Award

8/1/07-7/31/09 (Co-Investigator, 15%) PI: Fink, Jeffrey

“Effect of Practice Guidelines on Care of Chronic Kidney Disease in the VHA”

NIH/NIDDK R21 DK075675

7/1/08-6/30/09 (PI, 1%)

“Determinants of nephrology referral among CKD patients in the Veterans Health Administration: a Bayesian Network analysis.”

National Kidney Foundation of Maryland

7/1/08-6/30/09 (PI, 1%)

“Trends in diagnostic imaging and gadolinium-based contrast exposure among CKD patients: data from the national Veterans Health Administration”

National Kidney Foundation of Maryland

10/1/08-9/30/09 (Co-Invest, 10%) PI: Fink

“Comparison of early versus delayed initiation of ESA in veterans with chronic kidney disease”

Amgen, Inc.

7/1/08-6/30/11 (Site-PI, 2%)

“A Prospective Cohort Study Evaluation the Incidence of Nephrogenic Systemic Fibrosis in Patients with Stage 3 to 5 Chronic Kidney Disease Undergoing MRI with the Injection of Multihance”

Bracco, Inc. MH-136

3/1/10-2/28/11 (Co-Invest, 10%) PI: DeFilippi

“Serial high sensitivity troponin testing in the ambulatory elderly: a new strategy for early identification of ‘at-risk’ individuals for new heart failure and myocardial infarction”

Roche, Inc.

Role: Co-investigator.

6/1/08-5/30/13 (Site PI, 12.5%) PI: Fried

VA Co-operative Studies Program

CSP #565: “VA-NEPHRON-D Study”

Role: Site PI; Member, Study Design Committee; Member, Executive Committee.

1/1/13-12/31/12 (Co-Investigator, 2%) PI: deFilippi

"Impact of moderate physical activity on the longitudinal trajectory of cardiac specific biomarkers of stress and injury"

Roche, Inc.

Role: Co-investigator.

3/1/13-2/28/14 (Co-Investigator, 5%) PI: deFilippi

“Serial measurements of Soluble ST2 in the Cardiovascular Health Study”

Critical Care Diagnostics, Inc.

Role: Co-Investigator .

7/1/10-6/31/14 (co-PI, 20%) PIs: Seliger, L. Katzel

(No-cost extension) “Neurocognition and Functional Performance in Older Veterans with CKD”

VA Rehabilitation Research & Development Merit Review Award E7200R

Role: Principal Investigator

7/1/10-6/30/15 (Co-Investigator, 10% Effort beginning 5/2013) PI: Watnick

“Baltimore PKD Research and Clinical Core Center”

NIH/NIDDK 30DK0908

Role: Co-Investigator; Co-Director, Clinical and Translational Core

7/1/10 – 6/30/15 (Significant contributor, 0%) PI: Mindikoglu

NIH/NIDDK 5K23DK089008-02

“Gender Disparity in Liver Transplantation”

Role: Significant Contributor

7/1/15-6/30/12 (Director, Clinical Core) PI: Watnick

NIH/NIDDK 2 P30DK090868-07

“Baltimore PKD Research & Clinical Core Center”

Role: Co-Investigator; Director, Clinical & Translational Core

9/1/10-8/30/14 (Co-Invest, 10%) PI: Waldstein

(NCE to 2015) “Race, Socioeconomic Status, and the Brain: HANDLS Scan Substudy. “

NIH/NIA 1 RO1 AG034161

Role: Co-Investigator

Publications:

Peer-reviewed journal articles

1. Greenstein VC*, Seliger SL, Zemon V, Ritch, R#. “Visual evoked potential assessment of the effects of glaucoma on visual subsystems.” Vision Res, 1998; 38(12): 1901-1911.

2. Seliger SL*, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO#. “HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.” Kidney Int 2002; 61(1):297-304.

3. Ball A*, Gillen DS, Sherrard D, Weiss NS, Emerson S, Seliger SL, Kestenbaum B, Stehman-Breen CO#. “The risk of hip fracture among dialysis and renal transplant patients.” JAMA 2002; 288:3014-18.

4. Fung F*, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball A, Stehman-Breen C#. “Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients.” Am J Kidney Dis 2002; 40(2):307-14

5. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger SL, Ball A, Stehman-Breen C. “Calcium channel blocker use and mortality among patients with end-stage renal disease.” Kidney Int 2002; 61:2157-2164.

6. Seliger SL*, Gillen DL, Longstreth WT, Kestenbaum B, Stehman-Breen CO#. “Elevated risk of stroke among patients with end-stage renal disease.” Kidney Int 2003; 64(2): 603-609.

7. Kestenbaum B*, Seliger SL, Easterling TR, Gillen DL, Critchlow CW, Stehman-Breen CO, Schwartz SM#. “Cardiovascular and thromboembolic events following hypertensive pregnancy.” Am J Kidney Dis 2003; 42(5):982-989.

8. Barr WG*, Seliger SL, Appel GB, Zuniga R, D’Agati V, Salmon J, Radhakrishnan J#. “Prognosis in proliferative lupus nephritis: the role of socioeconomic status and race/ethnicity.” Nephrol Dial Transpl 2003; 18:2039-2046.

9. Seliger SL*, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO#. “Risk factors for incident stroke among ESRD patients.” J Am Soc Nephrol 2003; 14: 2623-2631.

10. Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO. “Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients.” Kidney Int 2003; 64(4): 1455-61.

11. Kestenbaum B*, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO#. “Parathyroidectomy rates in the United States: 1990-1999.” Kidney Int 2004; 65(1): 282-288.

12. Seliger SL*, Siscovick DS, Stehman-Breen CO, Gillen DL, Fitzpatrick A, Bleyer A, Kuller LH#. “Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study”. J Am Soc Nephrol 2004; 15(7):1904-11.

13. Kestenbaum B*, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C#. “Survival following parathyroidectomy among United States dialysis patients.” Kidney Int 2004; 66(5):2010-6.

14. Fried LF*, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman A# “Inflammatory and Prothrombotic Markers and the progression of renal disease in elderly individuals.” J Am Soc Nephrol, 2004; 15:3184-91.

15. Kestenaum B*, Sampson JN, Rudser KB, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL#. “Serum Phosphate levels and mortality risk among persons with chronic kidney disease.” J Am Soc Nephrol, 2005 Feb; 16(2):520-528.

16. Shlipak M*, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C#. “Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons.” New Engl J Med, 2005: 352(20): 2049-60.

17. Seliger SL*, Longstreth WT, Katz R, Manolio T, Fried LF, Shlipak M, Stehman-Breen CO, Sarnak M, Gillen DL, Bleyer A, Siscovick DS#. “Cystatin C and Subclinical Brain Infarction”. J Am Soc Nephrol, 2005; 16(12): 3721-7.

18. Jones-Burton C*, Seliger SL, Brown J, Stackiewicz L, Hsu VD, Fink JC#. “Racial Variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking.” Nephrol Dial Transpl, 2005; 20(12): 2739-45.

19. O’Hare AM*, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, Siscovick DS, Shlipak MG#. “Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study.” Arch Int Med 2005; 162(22): 2666-70.

20. Smith JM*, Rudser K, Gillen D, Kestenbaum B, Seliger S, Weiss N, McDonald RA, Davis CL, Stehman-Breen C#. “Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System.” Transplantation 2006; 81(2): 175-180.

21. Young BA*, Rudser K, Kestenbaum B, Seliger SL, Andress D, Boyko EJ#. “Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS”. Kidney Int 2006; May;69(9):1691-8

22. Shlipak MG*, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL Kestenbaum B, Psaty B, Tracy RP, Siscovick DS#. “Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.” Ann Int Med 2006; 154(4): 237-46.

23. Fried LF*, Shlipak MG, Stehman-Breen C, Mittalhenkle A, Seliger S, Sarnak M, Robbins J, Siscovick D, Harris TB, Newman AB, Cauley JA# “Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study.” J Gerontol A Biol Sci Med Sci 2006 Jul;61(7):743-8

24. Fried LF*, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, Sarnak M, Siscovick D, Harris T, Cauley J, Newman AB, Robbins J#. “Association of kidney function with incident hip fracture in older adults.” J Am Soc Nephrol 2007 Jan;18(1):282-6.

25. Jones-Burton C*, Seliger SL Scherer RW, Mishra SI, Vessal G, Brown J, Weir MR, Fink JC#. “Cigarette Smoking and incident chronic kidney disease: a systematic review.” Am J Nephrol 2007; 27(4) 342-51

26. Fink JC*, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P, Seliger SL#. “Center effects in anemia management of dialysis patients”. J Am Soc Nephrol 2007; 18(2): 646-53.

27. DeFilippi CR*, Seliger SL, Maynard S, Christenson RH#. “Impact of renal disease on natriuretic Peptide testing for diagnosing decompensated heart failure and predicting mortality.” Clin Chem, 2007; 53: 1511-9.

28. Spolter YS, Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. “The relationship between dialysis performance measures: adequacy and anemia management.” Am J Kidney Dis 2007 Nov; 50(5):774-81.

29. Kestenbaum B*, Rudser KD, Shlipak MG, Fried LF, Newman AB, Katz R, Sarnak MJ, Seliger S, Stehman-Breen C, Prineas R, Siscovick DS#. “Kidney function, electrocardiographic findings, and cardiovascular events among older adults.” Clin J Am Soc Nephrol 2007 May;2(3):501-8.

30. Seliger SL*, Katzel LI, Fink JC, Weir MR, Waldstein SR#. “Renal function and cardiovascular response to mental stress.” Am J Nephrol 2008; 28(2):304-10.

31. Sarnak MJ*, Katz R, Fried LF, Siscovick D, Kestenbaum B, Seliger S, Rifkin D, Tracy R, Newman AB, Shlipak MG#. “Cystatin C and aging success.” Arch Intern Med 2008 Jan 28;168(2):147-53.

32. Moran A*, Katz R, Smith NL, Fried LF, Sarnak MJ, Seliger SL, Psaty B, Siscovick DS, Gottdiener JS, Shlipak MG#. “Cystatin C concentrations as a predictor of systolic and diastolic heart failure.” J Card Fail 2008; 14(1):19-26.

33. de Boer IH*, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B#. “Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis.” Clin J Am Soc Nephrol 2008 Jan;3(1):125-32.

34. de Boer IH*, Astor BC, Kramer H, Palmas W, Rudser K, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B#. “Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA).” Atherosclerosis, 2008 Mar; 197(1):407-14.

35. Mittalhenkle A*, Stehman-Breen CO, Shlipak MG, Fried LF, Katz R, Young BA, Seliger S, Gillen D, Newman AB, Psaty BM, Siscovick D#. “Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study.” Clin J Am Soc Nephrol. 2008 Mar;3(2):450-6.

36. Kreyenbuhl J*, Medoff DR, Seliger SL, Dixon LB#. “Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes”. Schizophr Res, 2008 Mar 17.

37. Nogueira JM*, Jacobs SC, Haririan A, Phelan MW, Weir MR, Seliger SL, Hurley HA, Cooper M#. “A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach.” Transpl Int. 2008 Sep;21(9):908-14

38. Seliger SL*, Zahn M, Hsu VD, Walker LD, Fink JC#. “Chronic kidney disease adversely influences patient safety.” J Am Soc Nephrol, 2008; 19(12):2414-9.

39. Adeney KL*, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR#. “Association of serum phosphate with vascular and valvular calcification in moderate CKD.” J Am Soc Nephrol 2009; 20(2): 381-7.

40. Fink JC*, Brown J, Hsu VD, Seliger SL, Walker L, Zhan M#. “CKD as an underrecognized threat to patient safety.” Am J Kidney Dis 2009; 53(4):681-8

41. Fried LF*, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P#; VA NEPHRON-D Investigators. “Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).” Clin J Am Soc Nephrol 2009; 4(2): 361-8.

42. Einhorn LM*, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC#. “The frequency of hyperkalemia and its significance in chronic kidney disease.” Arch Int Med 2009; Jun 22; 169(12):1156-62.

43. Moen MF*, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, Fink JC#. “Frequency of hypoglycemia and its significance in chronic kidney disease.” Clin J Am Soc Nephrol 2009; 4(6): 1121-7.

44. Elias MF*, Elias PK, Seliger SL, Narsipur SS, Dore GA, Robbins MA#. “Chronic kidney disease, creatinine and cognitive functioning.” Nephrol Dial Transplant 2009; 24(8): 2246-52.

45. Waldstein SR*, Wendell CR, Seliger SL, Ferrucci L, Metter EJ, Zonderman AB.# “Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging.” J Am Geriatr Soc. 2010 Jan; 58(1):38-43.

46. DeFilippi CR*, Christenson RG,. Gottdiener JS, Kop WJ, Seliger SL#. “Dynamic Cardiovascular Risk Assessment in Elderly People: The Role of Repeated N-Terminal Pro–B-Type Natriuretic Peptide Testing.” J Am Coll Cardiol, 2010: 55(5):441-450.

47. Christenson RH*, Azzazy HM, Duh SH, Maynard S, Seliger SL, Defilippi CR#. Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. Clin Chem. 2010 Apr;56(4):633-41.

48. Waldstein SR*, Wendell CR, Seliger SL, Ferruci L, Metter EJ, Zonderman AB#. “Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore Longitudinal study of aging.” J Am Geriatr Soc 2010; 58(1):38-43.

49. Chapin E*, Zhan M, Hsu VD, Seliger SL, Walker LD, Fink JC#. “Adverse safety events in chronic kidney disease: the frequency of "multiple hits". Clin J Am Soc Nephrol 2010; 5(1):95-101.

50. Seliger SL*, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker L, Chang C-F, Fink JC#. “Timing of Erythropoiesis-stimulating agent (ESA) initiation and adverse outcomes in non-dialysis CKD: a propensity-matched observational study.” Clin J Am Soc Nephrol 2010 May; 5(5):882-8.

51. Yaffe K*, Ackerson L, Tamura MK, Le Blanc P, Kusek JW, Sehgal AR, Cohen D, Anderson C, Appel L, Desalvo K, Ojo A, Seliger S, Robinson N, Makos G, Go AS#. “Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study.” J Am Geriatr Soc 2010; 58(2): 338-45.

52. Lawler EV*, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, Gaziano JM, Bradbury BD#. “Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.” Nephrol Dial Transplant 2010; 25(7):2237-44.

53. deFilippi CR*, deLemos JA, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL#. “Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.” JAMA 2010; 304(22):2494-2502.

54. Aguilar MI*, O'Meara ES, Seliger S, Longstreth WT Jr, Hart RG, Pergola PE, Shlipak MG, Katz R, Sarnak MJ, Rifkin DE#. “Albuminuria and the risk of incident stroke and stroke types in older adults.” Neurology 2010 Oct 12;75(15):1343-50.

55. Mindikoglu AL*, Regev A, Seliger SL, Magder LS#. “Gender disparity in liver transplant waiting-list mortality: the importance of kidney function.” Liver Transpl 2010 Oct;16(10):1147-57

56. Kop WJ*, Seliger SL, Fink JC, Katz R, Odden MC, Fried LF, Rifkin DE, Sarnak MJ, Gottdiener JS#. “Longitudinal association of depressive symptoms with rapid kidney function decline and adverse clinical renal disease outcomes.” Clin J Am Soc Nephrol 2011 Apr;6(4):834-44.

57. Dalrymple LS*, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L#. “Chronic kidney disease and the risk of end-stage renal disease versus death.” J Gen Intern Med. 2011;26(4):379-85

58. Kurella Tamura M*, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, Messé SR, Sehgal AR, Kusek J, DeSalvo KB, Cornish-Zirker D, Cohan J, Seliger SL, Chertow GM, Go AS#. “Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study.” Clin J Am Soc Nephrol 2011 Feb;6(2):248-56.

59. Mindikoglu AL*, Raufman JP, Seliger SL, Howell CD, Magder LS#. “Simultaneous liver-kidney versus liver transplantation alone in patients with end-stage liver disease and kidney dysfunction not on dialysis.” Transplant Proc 2011 Sep;43(7):2669-77

60. van den Broek KC*, Defilippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ#. “Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality.” Am J Cardiol 2011 Mar 1;107(5):723-9.

61. Seliger SL*, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC#. “Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.” Kidney Int 2011; 80(3):288-94.

62. deFilippi CR*, Christenson RH, Kop WJ, Gottdiener JS, Zhan M, Seliger SL#. “Left Ventricular Ejection Fraction Assessment in Older Adults: An Adjunct to Natriuretic Peptide Testing to Identify Risk of New-Onset Heart Failure and Cardiovascular Death?” J Am Coll Cardiol 2011; 58(14): 1497-506.

63. Scialla JJ*, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS#. “Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.” Clin J Am Soc Nephrol 2011;6(11):2612-9

64. Schleichert RA*, Seliger SL, Zhan M, Gaspari AA#. “Nephrogenic systemic fibrosis and diabetes mellitus.” Arch Dermatol 2012 Feb;148(2):255-7.

65. Kop WJ*, Gottdiener JS, deFilippi CR, Barasch E, Seliger SL, Jenny NS, Christenson RH#. “Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged >=65 years with heart failure.” Circ Heart Fail 2012 Jul 1;5(4):406-13

66. Diamantidis CJ*, Seliger SL, Zhan M, Walker L, Rattinger GB, Hsu VD, Fink JC#. “A Varying Patient Safety Profile Between Black and Nonblack Adults With Decreased Estimated GFR.” Am J Kidney Dis 2012;60(1):47-53

67. deFilippi CR*, Seliger SL, Kelley W, Duh S-H, Hise M, Christenson R, Wolf M, Gaggin H; Januzzi J #. “Interpreting Cardiac Troponin Results from Highly Sensitive Assays in Chronic Kidney Disease Patients Without Acute Coronary Syndromes.” Clin Chem 2012; 2012 Sep;58(9):1342-51.

68. deFilippi CR*, de Lemos JA, Tkazcuk AT, Christenson RH, Carnethon M, Siscovick DS, Gottdiener JS, Seliger SL#. “ Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults”. J Am Coll Cardiology, 2012 Dec 18;60(24):2539-47

69. Roshanravan B*, Khatri M, Robinson-Cohen C, Levin G, Patel KV, de Boer IH, Seliger S, Ruzinski J, Himmelfarb J, Kestenbaum B#. “A prospective study of frailty in nephrology-referred patients with CKD.” Am J Kidney Dis 2012 Dec;60(6):912-21.

70. Smith K*, deFilippi C, Isakova T, Gutiérrez OM, Laliberte K, Seliger S, Kelley W, Duh SH, Hise M, Christenson R, Wolf M, Januzzi J#. “Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD”. Am J Kidney Dis. 2013 Jan;61(1):67-73

71. Neeland IJ*, Drazner MH, Berry JD, Ayers CR, deFilippi C, Seliger SL, Nambi V, McGuire DK, Omland T, de Lemos JA#. “Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.” J Am Coll Cardiol 2013; 61(2): 187-95.

72. Longstreth WT Jr*, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR#. “Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy.” Stroke. 2013 Mar;44(3):714-9.

73. Yaffe K*, Ackerson L, Hoang TD, Go AS, Maguire MG, Ying GS, Daniel E, Bazzano LA, Coleman M, Cohen DL, Kusek JW, Ojo A, Seliger S, Xie D, Grunwald JE#. “Retinopathy and cognitive impairment in adults with CKD.” Am J Kidney Dis, 2013;61(2):219-27.

74. Spencer RJ*, Wendell CR, Giggey PP, Seliger SL, Katzel LI, Waldstein SR# “Judgment of Line Orientation: an examination of eight short forms.” J Clin Exp Neuropsychol 2013; 35(2):160-6

75. Davey A*, Elias MF, Robbins MA, Seliger SL, Dore GA#. “Decline in renal functioning is associated with longitudinal decline in global cognitive functioning, abstract reasoning and verbal memory”. Nephrol Dial Transpl 2013; 28(7): 1810-9.

76. Roshanravan B*, Robinson-Cohen C, Patel KV, Ayers E, Littman AJ, de Boer IH, Ikizler TA, Himmelfarb J, Katzel LI, Kestenbaum B#, Seliger S#. “Association between physical performance and all-cause mortality in CKD.” J Am Soc Nephrol 2013; 24(5): 822-30.

77. Murray AM*, Seliger S, Lakshminarayan K, Herzog CA, Solid CA#. “Incidence of stroke before and after dialysis initiation in older patients” J Am Soc Nephrol 2013 24(7): 1166-73.

78. Mindikoglu AL*, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS#. “Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis.” Hepatology 2013 Jun 6[Epub ahead of print]

79. Glick D*, deFilippi CR, Christenson R, Gottdiener JS, Seliger SL#. “Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community dwelling older adults at low baseline risk” J Am Coll Cardiology HF 2013; 353-360.

80. Fried LF*, Emmanuale N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P#. “Combined Angiotensin Inhibition for Treatment of Diabetic Nephropathy” N Engl J Med, 2013 Nov 14;369(20):1892-903

81. Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA. “Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay.” J Am Coll Cardiol 2014; 15;63(14):1441-8.

82. Weiner DE, Seliger SL#. “Cognitive and physical function in chronic kidney disease.” Curr Opinion Nephrol Hypertens. 2014 May;23(3):291-7.

83. Mindikoglu AL*, Dowling TC, Wong-You-Cheong JJ, Christenson RH, Magder LS, Hutson WR*, Seliger SL, Weir MR#. “A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements” Am J Nephrol 2014;39(6):543-52.

84. Rahman M*, Xie D, Feldman HI, Go AS, He J, Kusek JW, Lash J, Miller III ER, Ojo A, Pan Q, Seliger SL, Steigerwalt S, Townsend RR#. “Association Between Chronic Kidney Disease Progression and Cardiovascular Disease: Results from the CRIC Study”. Am J Nephrol. 2014;40(5):399-407.

85. Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, Park M, Sarnak M, Seliger S, Shlipak M. “NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults”. Clin J Am Soc Nephrol. 2015 6;10(2):205-14

86. Seliger SL*, Wendell CR, Waldstein SR, Ferruci L, Zonderman AB. “Renal Function and Long-term Decline in Cognitive Function: The Baltimore Longitudinal Study of Aging”. Am J Nephrol 2015, 2015, 41(4-5):305-12.

87. Seliger SL*, de Lemos J, Neeland IJ, Christenson R, Gottdiener J, Drazner MH, Berry J, Sorkin J, deFilippi C#. “Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study)”. JACC: Heart Failure, 2015 Jun;3(6):445-55.

88. Parikh RH, Seliger SL, de Lemos J, Nambi V, Christenson R, Ayers C, Sun W, Gottdiener JS, Kuller LH, Ballantyne C, deFilippi CR. “Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis.” Clin Chem 2015;61(12):1524-31.

89. Sandsmark DK, Messé SR, Zhang X, Roy J, Nessel L, Lee Hamm L, He J, Horwitz EJ, Jaar BG, Kallem RR, Kusek JW, Mohler ER 3rd, Porter A, Seliger SL, Sozio SM, Townsend RR, Feldman HI, Kasner SE. “Proteinuria, but Not eGFR, Predicts Stroke Risk in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort Study.” Stroke 2015 Aug;46(8):2075-80

90. Bansal N, Katz R, Seliger S, DeFilippi C, Sarnak MJ, Delaney JA, Christenson R, de Boer IH, Kestenbaum B, Robinson-Cohen C, Ix JH, Shlipak MG. “Galectin-3 and Soluble ST2 and Kidney Function Decline in Older Adults: The Cardiovascular Health Study (CHS).” Am J Kidney Dis. 2016 Jun;67(6):994

91. Kurella Tamura M, Vittinghoff E, Yang J, Go AS, Seliger SL, Kusek JW, Lash J, Cohen DL, Simon J, Batuman V, Ordonez J, Makos G, Yaffe K. “Anemia and risk for cognitive decline in chronic kidney disease.” BMC Nephrol 2016 Jan 28;17:13

92. Torres RV, Elias MF, Seliger S, Davey A, Robbins MA.” Risk for cognitive impairment across 22 measures of cognitive ability in early-stage chronic kidney disease.” Nephrol Dial Transplant 2016 Mar 8 [Epub ahead of print]

93. Seliger SL*, Salimi S, Pierre V, Giffuni J, Katzel L and Parsa A#. “Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults”. BMC Nephrol 2016; 17:82.

94. Parikh RH, Seliger SL, Christenson R, Gottdiener JS, Psaty BM, deFilippi CR. “Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community-Dwelling Population.” J Am Heart Assoc 2016 Aug 1;5(8). pii: e003188

95. deFilippi CR*, de Lemos JA, Newman AB, Guralnik JM, Christenson RH, Pahor M, Church T, Espeland M, Krithevsky SB, Stafford R, Seliger SL#. “Impact of moderate physical activity on the longitudinal trajectory of a cardiac specific biomarker of injury: Results from a randomized pilot study of exercise intervention. Am Heart J 2016; Sep;179:151-6

Journal Articles – Non-refereed

1. Seliger SL*, Davis C, Stehman-Breen, C#. “Gender and the progression of renal disease.” Curr Opin Nephrol Hypertens 2001 Mar;10(2):219-25.

2. Seliger SL*, Stehman-Breen CO. “Are statins underutilized among dialysis patients?” Seminars in Dialysis, 2003; 16(3):179-85.

3. Chang A*, Logar CM, Finn LS, Alpers CE, Seliger SL#. “A rare cause of necrotizing and crescentic glomerulonephritis in a young adult male.” Am J Kidney Dis 2005, 45(5):956-60.

4. Seliger SL*. “Inflammation and dyslipidemia in nephropathy: an epidemiologic perspective.” Kidney Int 2006; 69(2): 206-8 [Invited Editorial].

5. Seliger SL*, Sarnak MJ. “Subclinical Vascular disease of the brain in dialysis patients” Am J Kidney Dis 2007; 50(1):8-10 [Invited Editorial]

6. Seliger SL*, Longstreth WJ#. “Lessons about brain vascular disease from that other pulsatile organ, the kidney”. Stroke 2008 Jan;39(1):5-6 [Invited Editorial]

7. deFilippi CR*, Seliger SL#. “Biomarkers for prognostication after acute coronary syndromes: new times and statistics.” J Am Coll Cardiol 2009; 54(4): 365-7 [Invited Editorial]

8. Seliger SL*. “Stroke in ESRD: the other cardiovascular disease.” Am J Kidney Dis 2009; 54(3): 403-5. [Invited Editorial].

9. Seliger SL*. “Comorbidity and confounding in ESRD”. Kidney Int, 2010; 77(2):83-5 [Invited Editorial].

10. Kalantari K, Seliger S*. “Stroke symptoms signal worse outcomes in patients with end-stage renal disease”. Neurology. 2012 Sep 4;79(10):960-1 [Invited editorial]

11. Seliger, SL*. “Physical Activity in ESRD – time to get moving”. Clin J Am Soc Nephrol, 2012 Dec;7(12):1927-9 [Invited Editorial].

12. Seliger SL*, Weiner DE. “Cognitive impairment in dialysis patients: focus on the blood vessels?” Am J Kidney Dis, 2013;61(2):187-90 [Invited Editorial].

13. Seliger SL*. “Physical activity in ESRD: time to get moving.” Clin J Am Soc Nephrol, 2012; 7(12):1927-9 [Invited Editorial].

14. Seliger SL*, Fried LF. “Serum potassium in dual renin-angiotensin-aldosterone system blockade”. Clin J Am Soc Nephrol,. 2014 Feb;9(2):219-21[Invited Editorial]

15. deFilippi CR, Seliger SL. “Natriuretic Peptide and cardiovascular risk: is it about "U"? J Am Heart Assoc. 2015 May 21;4(5). [Invited Editorial].

16. Seliger SL*. “Frailty and Cognitive Impairment in ESRD: Brain-Body Connections.” Clin J Am Soc Nephrol 2015 Dec 7;10(12):2104-6. [Invited Editorial]

Book Chapter

1. Waldsetin SR*, Rice-Wendell CR, Hosey MH, Seliger SL, Katzel LI#. “Cardiovascular Disease and Neurocognitive Function”, in Handbook of Medical Neuropsychology, Carol L. Armstrong & Lisa Morrow editors. New York: Springer LLC, pgs 69-100.

Abstracts

1. Seliger SL*, Sampson J, Kestenbaum B, Young B, Rudser B, Brockenbrough A, Andress D, Sherrard DJ#. “Simvastatin use and cardiovascular outcomes among veterans with chronic renal insufficiency (CRI).” J Am Soc Nephrol, 2004.

2. Seliger SL*, Betz J, Zhuo J, Gullapali R, Katzel LI, Fink J, Waldstein SR#. “Cognitive Dysfunction in CKD: Role of Brain Atrophy and White Matter Disease”. J Am Soc Nephrol 2008: 524A.

3. Stephen L Seliger*; Robert Christenson; John Gottdiener; Willem J Kop; Christopher deFilippi#. “Longitudinal Changes in NT-proBNP Predict New Onset Heart Failure in Community-Dwelling Older Adults: The Cardiovascular Health Study.” Circulation. 2008;118:S_1092.

4. Christopher Defilippi*, Robert Christenson, John Gottdiener, Willem J Kop, and Stephen L Seliger#. “The Plasticity of Cardiovascular Risk in the Elderly: A role for serial NT-proBNP measurement.” Circulation, Oct 2008; 118: S_1130.

5. Seliger SL*, Walker L, Hsu VD, Fink JC#. “Trends in Iodinated Contrast and Gadolinium-Based Contrast Exposure in a National CKD Cohort: 2002-2006”. J Am Soc Nephrol 2009, 20:480A.

6. Seliger SL*, Betz JF, Steinbrenner G, Waldstein SR, Katzel LI#. “Physical Function and Subclinical Brain Disease in Stage 3-4 CKD” J Am Soc Nephrol 2010; 21: 658A.

Major Invited Speeches

1. “Chronic Kidney Disease and Patient Safety Indicators”. American Society of Nephrology Annual Meeting, San Francisco, Nov 3, 2007.

2. “Longitudinal Changes in NT-proBNP Predict New Onset Heart Failure in Community-Dwelling Older Adults: The Cardiovascular Health Study”. American Heart Association Scientific Sessions New Orleans, LA, November 2008.

3. “Physiologic versus Chronological Age: Role of the Lab”. American Association of Clinical Chemistry Chronic Disease Conference, Newport Beach, CA, May 6, 2009.

4. “Longitudinal Changes in high-sensitivity Troponin T predict New Onset Heart Failure in community-dwelling Older Adults”. American Heart Association Scientific Sessions Chicago, IL, November 2010.

5. “Kidney-Brain Interactions in Older Adults: Effects on Cognitive and Physical Function”. Department of Medicine Grand Rounds, University of Maryland School of Medicine, Baltimore, MD July 2011.

6. “Physical Activity and Long-Term changes in high-sensitivity Troponin T in the elderly”. European Society of Cardiology Congress, Paris, France, August 31 2011.

7. “Physical and Cognitive Impairment in older adults with CKD –

Rationale for a Randomized Controlled Clinical Trial.” Renal Grand Rounds, Johns Hopkins University School of Medicine, Baltimore, January 26 2012.

8. “Physical and Cognitive Impairment in older adults with CKD –

Rationale for a Randomized Controlled Clinical Trial.” Grand Rounds, Division of Nephrology and Hypertension, Georgetown University Hospital, Washington, DC, Feb 10 2012.

9. “Physical and Cognitive Impairment in older adults with CKD –

Rationale for a Randomized Controlled Clinical Trial.” Grand Rounds, Division of Nephrology, Penn State Hershey Medical Center, April 10, 2012.

10. “Stroke and CKD/ESRD”. Invited lecture, 2012 American Society of Nephrology Renal Week San Diego, CA, October 31, 2012.

11. “ESA’s, Stroke Risk, and Cognitive Function”. Invited Lecture, 2013 National Kidney Foundation Spring Meeting, Orlando FL, April 3, 2013.

12. “Determinants of Progressive CKD Detected at KEEP Screenings”. Invited Lecture, 2013 National Kidney Foundation Spring Meeting, Orlando FL, April 5, 2013.

13. “Diabetic Nephropathy – Update and Role of Renin-Angiotensin Aldosterone Antagonism” American College of Physicians Delaware Chapter Lower Shores Annual Meeting, Reheboth Beach DE, October 25th 2014.

14. “Renal Rehabilitation – beyond ‘Replacement Therapy’”. University of Maryland School of Medicine, Department of Medicine Grand Rounds, Baltimore MD, June 10th, 2015.

15. “Frailty and Cognitive Function in ESRD”. National Kidney Foundation Spring Clinical meeting, Boston, MA April 30th, 2016

16. “Rehabilitation in Renal Disease:  Effects on Physical and Cognitive Performance”. Rehabilitation Research at NIH: Moving the Field Forward, Bethesda, MD May 25th

2016

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download